These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 36359837)

  • 1. The Role of HSP90 Inhibitors in the Treatment of Cardiovascular Diseases.
    Qi S; Yi G; Yu K; Feng C; Deng S
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding.
    Woodford MR; Dunn DM; Blanden AR; Capriotti D; Loiselle D; Prodromou C; Panaretou B; Hughes PF; Smith A; Ackerman W; Haystead TA; Loh SN; Bourboulia D; Schmidt LS; Marston Linehan W; Bratslavsky G; Mollapour M
    Nat Commun; 2016 Jun; 7():12037. PubMed ID: 27353360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extracellular heat shock protein 90: a role for a molecular chaperone in cell motility and cancer metastasis.
    Tsutsumi S; Neckers L
    Cancer Sci; 2007 Oct; 98(10):1536-9. PubMed ID: 17645779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
    Giulino-Roth L; van Besien HJ; Dalton T; Totonchy JE; Rodina A; Taldone T; Bolaender A; Erdjument-Bromage H; Sadek J; Chadburn A; Barth MJ; Dela Cruz FS; Rainey A; Kung AL; Chiosis G; Cesarman E
    Mol Cancer Ther; 2017 Sep; 16(9):1779-1790. PubMed ID: 28619753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.
    Georgakis GV; Younes A
    Future Oncol; 2005 Apr; 1(2):273-81. PubMed ID: 16555999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Right Tool for the Job: An Overview of Hsp90 Inhibitors.
    Koren J; Blagg BSJ
    Adv Exp Med Biol; 2020; 1243():135-146. PubMed ID: 32297216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions.
    Hong DS; Banerji U; Tavana B; George GC; Aaron J; Kurzrock R
    Cancer Treat Rev; 2013 Jun; 39(4):375-87. PubMed ID: 23199899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesis.
    Acquaviva J; He S; Sang J; Smith DL; Sequeira M; Zhang C; Bates RC; Proia DA
    Mol Cancer Res; 2014 May; 12(5):703-13. PubMed ID: 24554781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
    Li L; Wang L; You QD; Xu XL
    J Med Chem; 2020 Mar; 63(5):1798-1822. PubMed ID: 31663736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Hsp90-Cdc37: A Promising Therapeutic Strategy by Inhibiting Hsp90 Chaperone Function.
    Wang L; Li L; Gu K; Xu XL; Sun Y; You QD
    Curr Drug Targets; 2017; 18(13):1572-1585. PubMed ID: 27231111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic target Hsp90 and cancer hallmarks.
    Miyata Y; Nakamoto H; Neckers L
    Curr Pharm Des; 2013; 19(3):347-65. PubMed ID: 22920906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Understanding of HSP90 as a Novel Therapeutic Target: An Emerging Approach for the Treatment of Cancer.
    Haque A; Alam Q; Alam MZ; Azhar EI; Sait KH; Anfinan N; Mushtaq G; Kamal MA; Rasool M
    Curr Pharm Des; 2016; 22(20):2947-59. PubMed ID: 27013225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting chaperones in transformed systems--a focus on Hsp90 and cancer.
    Chiosis G
    Expert Opin Ther Targets; 2006 Feb; 10(1):37-50. PubMed ID: 16441227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of HSP90 molecular chaperones: moving into the clinic.
    Garcia-Carbonero R; Carnero A; Paz-Ares L
    Lancet Oncol; 2013 Aug; 14(9):e358-69. PubMed ID: 23896275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.
    Messaoudi S; Peyrat JF; Brion JD; Alami M
    Expert Opin Ther Pat; 2011 Oct; 21(10):1501-42. PubMed ID: 21689065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 and its inhibitors.
    Hao H; Naomoto Y; Bao X; Watanabe N; Sakurama K; Noma K; Motoki T; Tomono Y; Fukazawa T; Shirakawa Y; Yamatsuji T; Matsuoka J; Takaoka M
    Oncol Rep; 2010 Jun; 23(6):1483-92. PubMed ID: 20428801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual screening based identification of miltefosine and octenidine as inhibitors of heat shock protein 90.
    Li L; Yang M; Li C; Liu Y
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Nov; 394(11):2223-2232. PubMed ID: 34406420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrocycles that inhibit the binding between heat shock protein 90 and TPR-containing proteins.
    Ardi VC; Alexander LD; Johnson VA; McAlpine SR
    ACS Chem Biol; 2011 Dec; 6(12):1357-66. PubMed ID: 21950602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function.
    Basso AD; Solit DB; Chiosis G; Giri B; Tsichlis P; Rosen N
    J Biol Chem; 2002 Oct; 277(42):39858-66. PubMed ID: 12176997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heat shock protein 90: the cancer chaperone.
    Neckers L
    J Biosci; 2007 Apr; 32(3):517-30. PubMed ID: 17536171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.